Item 8.01 Other Events.

On November 25, 2008, Pharmacyclics, Inc. a Delaware corporation (the "Registrant"), announced that the company has completed a Phase 1 clinical trial with PCI-27483, the company's novel, first-in-class small-molecule Factor VIIa inhibitor. The trial was conducted in sixteen (16) healthy volunteers to evaluate the safety and pharmacologic effect of PCI-27483. A single administration of PCI-27483 resulted in a linear dose response in the International Normalized Ratio (INR), a routine laboratory test used to assess the level of anticoagulation (blood-thinning).

The foregoing description is qualified in its entirety by reference to the Registrant's Press Release dated November 25, 2008, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. Exhibit No. Description
99.1 Press Release of Pharmacyclics, Inc. dated November 25, 2008.

---